ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions
ChromaDex Corp. (NASDAQ:CDXC) celebrates its 25th anniversary as a pioneer in NAD+ research and healthy aging solutions. Founded in 1999, ChromaDex has evolved from an analytical testing company to a leader in developing proprietary ingredients for dietary supplements. The company's flagship product, Tru Niagen®, is the top NAD+ supplement for healthy aging in the U.S., with over 8 million bottles sold.
Key achievements include:
- Licensing patents for Dr. Charles Brenner's nicotinamide riboside (NR) research in 2012
- Launching Niagen®, the first patented form of NR, in 2013
- Introducing pharmaceutical-grade Niagen+™ for intravenous therapy in 2024
- Establishing the ChromaDex External Research Program (CERP™), which has facilitated over 275 research agreements globally
- Building a portfolio of 90+ patents related to NAD+ precursors
To mark this milestone, ChromaDex is offering a 25% discount on lifelong Tru Niagen® subscriptions and one-time purchases until September 12, 2024.
ChromaDex Corp. (NASDAQ:CDXC) celebra il suo 25° anniversario come pioniere nella ricerca sul NAD+ e nelle soluzioni per l'invecchiamento sano. Fondata nel 1999, ChromaDex si è evoluta da un'azienda di analisi a leader nello sviluppo di ingredienti proprietari per integratori alimentari. Il prodotto di punta dell'azienda, Tru Niagen®, è il principale integratore di NAD+ per un invecchiamento sano negli Stati Uniti, con oltre 8 milioni di bottiglie vendute.
Le principali realizzazioni includono:
- Licensing dei brevetti per la ricerca del Dr. Charles Brenner sulla riboside di nicotinamide (NR) nel 2012
- Lancio di Niagen®, la prima forma brevettata di NR, nel 2013
- Introduzione di Niagen+™, di grado farmaceutico, per terapia endovenosa nel 2024
- Creazione del ChromaDex External Research Program (CERP™), che ha facilitato oltre 275 accordi di ricerca a livello globale
- Costruzione di un portafoglio di oltre 90 brevetti relativi ai precursori del NAD+
Per celebrare questo traguardo, ChromaDex offre uno sconto del 25% su abbonamenti a vita e acquisti una tantum di Tru Niagen® fino al 12 settembre 2024.
ChromaDex Corp. (NASDAQ:CDXC) celebra su 25° aniversario como pionero en la investigación sobre NAD+ y soluciones para un envejecimiento saludable. Fundada en 1999, ChromaDex ha evolucionado de ser una empresa de pruebas analíticas a líder en el desarrollo de ingredientes patentados para suplementos dietéticos. El producto insignia de la compañía, Tru Niagen®, es el principal suplemento de NAD+ para un envejecimiento saludable en EE. UU., con más de 8 millones de botellas vendidas.
Los logros clave incluyen:
- Licenciamiento de patentes para la investigación en ribosido de nicotinamida (NR) del Dr. Charles Brenner en 2012
- Lanzamiento de Niagen®, la primera forma patentada de NR, en 2013
- Introducción de Niagen+™, de grado farmacéutico, para terapia intravenosa en 2024
- Establecimiento del ChromaDex External Research Program (CERP™), que ha facilitado más de 275 acuerdos de investigación a nivel mundial
- Construcción de un portafolio de más de 90 patentes relacionadas con los precursores de NAD+
Para conmemorar este hito, ChromaDex ofrece un 25% de descuento en suscripciones de por vida a Tru Niagen® y compras únicas hasta el 12 de septiembre de 2024.
ChromaDex Corp. (NASDAQ:CDXC)는 NAD+ 연구 및 건강한 노화 솔루션의 선구자로서 25주년을 기념합니다. 1999년에 설립된 ChromaDex는 분석 테스트 회사에서 식이 보충제를 위한 독점 성분 개발을 선도하는 기업으로 발전했습니다. 회사의 주력 제품인 Tru Niagen®은 미국에서 건강한 노화를 위한 최고의 NAD+ 보충제로, 800만 병 이상이 판매되었습니다.
주요 성과는 다음과 같습니다:
- 2012년에 Charles Brenner 박사의 니코티나마이드 리보사이드(NR) 연구에 대한 특허 라이선스 취득
- 2013년에 NR의 첫 번째 특허 형태인 Niagen® 출시
- 2024년에 정맥 요법을 위한 제약 등급의 Niagen+™ 소개
- ChromaDex External Research Program(CERP™) 설립, 전 세계적으로 275개 이상의 연구 계약을 용이하게 함
- NAD+ 전구체와 관련된 90개 이상의 특허 포트폴리오 구축
이 이정표를 기념하기 위해 ChromaDex는 Tru Niagen®의 평생 구독 및 일회성 구매에 대해 25% 할인을 제공하며, 해당 서비스는 2024년 9월 12일까지 이용 가능합니다.
ChromaDex Corp. (NASDAQ:CDXC) fête son 25ème anniversaire en tant que pionnier dans la recherche sur le NAD+ et les solutions pour un vieillissement sain. Fondée en 1999, ChromaDex s'est développée d'une société d'analyses à un leader dans le développement d'ingrédients innovants pour les compléments alimentaires. Le produit phare de l'entreprise, Tru Niagen®, est le meilleur complément de NAD+ pour un vieillissement sain aux États-Unis, avec plus de 8 millions de bouteilles vendues.
Les principales réalisations incluent :
- Licenciement des brevets pour la recherche du Dr. Charles Brenner sur le riboside de nicotinamide (NR) en 2012
- Lancement de Niagen®, la première forme brevetée de NR, en 2013
- Introduction de Niagen+™, de qualité pharmaceutique, pour les thérapies intraveineuses en 2024
- Établissement du ChromaDex External Research Program (CERP™), qui a facilité plus de 275 accords de recherche à l'échelle mondiale
- Constitution d'un portefeuille de plus de 90 brevets liés aux précurseurs du NAD+
Pour marquer cet événement, ChromaDex propose une remise de 25 % sur les abonnements à vie et les achats uniques de Tru Niagen® jusqu'au 12 septembre 2024.
ChromaDex Corp. (NASDAQ:CDXC) feiert ihr 25-jähriges Jubiläum als Pionier in der NAD+-Forschung und Lösungen für gesundes Altern. Gegründet im Jahr 1999 hat sich ChromaDex von einem Unternehmen für analytische Tests zu einem führenden Anbieter von proprietären Zutaten für Nahrungsergänzungsmittel entwickelt. Das Flaggschiffprodukt des Unternehmens, Tru Niagen®, ist das führende NAD+-Supplement für gesundes Altern in den USA, mit über 8 Millionen verkauften Flaschen.
Wichtige Erfolge umfassen:
- Lizenzierung der Patente für die Forschung von Dr. Charles Brenner zur Nicotinamid-Ribosid (NR) im Jahr 2012
- Einführung von Niagen®, der ersten patentierten Form von NR, im Jahr 2013
- Einführung von Niagen+™, pharmazeutische Qualität für die intravenöse Therapie im Jahr 2024
- Einrichtung des ChromaDex External Research Program (CERP™), das weltweit über 275 Forschungsvereinbarungen erleichtert hat
- Aufbau eines Portfolios von über 90 Patenten zu NAD+-Vorfahren
Um diesen Meilenstein zu feiern, bietet ChromaDex einen Rabatt von 25 % auf lebenslange Abonnements und Einmalkäufe von Tru Niagen® bis zum 12. September 2024 an.
- None.
- None.
Commemorating a quarter of a century with an exclusive
To celebrate this milestone, ChromaDex is offering an exclusive
A Legacy of Innovation and Leadership
Founded in 1999, ChromaDex’s journey began in the analytical testing space and supplying reference standard materials to researchers and other companies. ChromaDex then transitioned its business to developing and selling proprietary ingredients in the food and dietary supplement space.
In 2004, Dr. Charles Brenner discovered the breakthrough that illuminated the process by which nicotinamide riboside (NR) increases cellular NAD+ levels. ChromaDex licensed the patents behind Dr. Brenner’s research in 2012, making this revolutionary science accessible worldwide. A year later, the company launched Niagen®, the world’s first patented form of NR and the most efficient, high-quality NAD+ precursor available.
Niagen has since become both the cornerstone for independent preclinical and clinical NAD+ research and the hero ingredient in the company’s dietary supplement line, available to consumers under the brand Tru Niagen. Today, Tru Niagen is the number one NAD+ supplement for healthy aging in the
Just this year, ChromaDex marked yet another milestone as it unveiled the first-of-its-kind pharmaceutical grade Niagen (patented nicotinamide riboside chloride or NRCl), branded Niagen+™. Available as Niagen IV and injections exclusively at clinics with a prescription, Niagen IV represents a significant advancement in intravenous therapy.
Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, commented, "Frank Jaksch founded ChromaDex as a reference standards business, a legacy that proudly endures today, reminding us that performing at the highest scientific and professional standard is in our DNA. We believe ChromaDex remains the gold standard in quality, efficacy, safety, and ethical business practices.”
The Gold Standard in Scientific Excellence and Quality
Over the past 25 years, ChromaDex has established itself as the gold standard in scientific rigor and quality. With more than 275 research agreements globally, 175+ peer-reviewed publications, and over 30 human clinical studies featuring Niagen, the ChromaDex External Research Program (CERP™) has been instrumental in advancing the scientific understanding of NAD+ and its role in age-related health conditions.
CERP, which celebrated its 10th anniversary just last year, has been a driving force behind this success, fostering collaborations with over 200 institutions, including the Mayo Clinic, the National Institute on Aging, and Harvard University. This program has generated over
The company’s robust patent portfolio now includes over 90 patents related to NAD+ precursors, including NR, NRH, NAR, and NMNH.
Dedicated to Healthy Aging for All
A never-before-seen
For additional information on ChromaDex, visit www.chromadex.com.
⤉Based on the top-selling dietary supplement brands by revenue per the largest US ecommerce marketplace [identified through a search dated March 1, 2023 – Feb. 29, 2024 using “NAD precursors”
Forward Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to sales and marketing activity, and ongoing research and development efforts. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
About ChromaDex:
ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality.
Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.
Niagen is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in
ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, to which ChromaDex regularly publishes copies of its press releases, news, and financial information.
†Based on the top-selling dietary supplement brands by revenue per the largest
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909499862/en/
ChromaDex Media Contact:
Kendall Knysch, Senior Director of Media Relations & Partnerships
310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
Source: ChromaDex Corporation
FAQ
What is ChromaDex Corp. (CDXC) celebrating in 2024?
How many bottles of Tru Niagen has ChromaDex (CDXC) sold?
What special offer is ChromaDex (CDXC) providing for its 25th anniversary?
What is Niagen+™ and when did ChromaDex (CDXC) introduce it?